In a phase 3 clinical trial, patients with cold agglutinin disease (CAD) treated with sutimlimab demonstrated improved haemoglobin levels, required fewer blood transfusions, and felt significantly less fatigued .
Sutimlimab is a first-in-class humanised monoclonal antibody that selectively inhibits the C1 complex of the classical complement pathway. Since C1 complement pathway overactivation is thought to drive CAD pathogenesis, the rationale was to evaluate whether sutimlimab could modify key disease outcomes such as haemolytic anaemia. There are currently no approved treatments for CAD.
Dr Alexander Röth (University of Duisburg-Essen, Germany) presented Part A of the open-label, single-arm, multicentre CARDINAL study, in which 22 CAD patients (average age of 71 years) received intravenous sutimlimab on days 0 and 7, followed by biweekly infusions for 26 weeks. Part B is the ongoing e...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Oral azacitidine improves overall survival in patients with AML in remission Next Article
Erythroferrone and skeletal changes associated with thalassaemia »
Table of Contents: ASH 2019
Sickle Cell Disease
Plenary Scientific Session
CAR T and Beyond
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.